Many FH patients cannot achieve adequate control of LDL-C levels with high-intensity statin therapy, and a cholesterol absorption inhibitor (ezetimibe) and PCSK9 inhibitor are the next-line classes of drugs [6]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.